Professor Seng Gee Lim, FRACP, FRCP, FAMS, MD, is Director of Hepatology at the Division of Gastroenterology and Hepatology, National University Health System, Singapore, and was previously Chief of Division. He graduated in 1980 from Monash Medical School completed his research MD at the Royal Free Hospital.
He is a member of the editorial boards for Liver International, Journal of Viral Hepatitis, Hepatology International, Alimentary Pharmacology and Therapeutics, Lancet Gastroenterology & Hepatology, and Evidence Based Internal Medicine Solutions, He is also on the advisory board of Gilead Sciences, Roche, Arbutus, Assembly, Springbank, Eisai, Abbvie and Abbott Diagnostics.
He is currently chairman of the Singapore Hepatology Conference and Science of HBV Cure Conference, and was previously the Chairman of the Asia Pacific Association for Study of the Liver (APASL) Liver Week 2013 Congress. He served as Governing Council member from 2014-2018 of the International Association for Study of Liver (IASL), and has been appointed to the AASLD Asia Pacific Regional Advisory Council in 2018. He is also governing council board member of International Coalition for Eradication for Hepatitis B (ICE-HBV) and a co-chair of the HBV Forum combination therapy committee. He is faculty at the Asia Pacific EBM workshop.
His research includes clinical trials of new treatments for chronic hepatitis B and C, and translational research in viral hepatitis, involving molecular biology and immunology of hepatitis B. He has published 253 peer reviewed publications and secured peer review grant funding worth >SGD $48 Million (>USD$35M), including the award of a SGD $25 million National Translational Clinical Research grant in 2015 to investigate eradication of HBV, which was recently renewed. In 2018 he was awarded the NMRC Clinician Scientist Award for research in HBV. His H index is 58.
